Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused by mutations of the LDL receptor (LDLR) gene. 1, 2 Hypercholestrolemia is the hallmark of FH, and homozygous FH patients die of ischemic heart disease secondary to severe atherosclerosis at an early age.
2 Pharmacotherapy of homozygous FH is unsatisfactory. 3 LDL apheresis is efficacious in lowering plasma cholesterol, but its effect is transient and treatment has to be repeated every 2 to 3 weeks. 4, 5 The lack of an effective treatment for FH prompted the exploration of gene therapy as an alternative approach to the management of this devastating disease.
The only clinical trial of somatic gene therapy for FH used an ex vivo approach in which hepatocytes isolated from FH patients and transduced with the LDLR gene using a retroviral vector were reimplanted in the patients. Only a marginal response to the treatment was evident. 6 In vivo gene therapy for FH has been tested only in animals. First generation adenovirus (FG-Ad)-mediated transfer of the LDLR gene to the liver of LDLR À/À mice 7 or Watanabe heritable hyperlipidemic rabbits 8, 9 led to significant but transient plasma cholesterol lowering. Adeno-associated virus (AAV)-mediated gene transfer using LDLR in LDLR À/À mice produced a minimal response compared with a much more robust response when a surrogate receptor, very low-density lipoprotein receptor (VLDLR), was used as the therapeutic gene. 10 The transient and incomplete nature of the lipid lowering after LDLR gene therapy using either FG-Ad or AAV is related at least in part to an immune response against the induced LDLR expression in mice lacking LDLR. 10, 11 The helper-dependent Ad (HD-Ad) [12] [13] [14] is the latest generation Ad that has been shown to have high transduction efficiency in vivo, and the transfer of apolipoprotein (apo) E to the liver of apoE À/À mice by this vector produced lifetime phenotypic correction of the hypercholesterolemia. 13 In this study we tested the efficacy of HD-Ads in the treatment of LDLR À/À mice. In addition to testing the cholesterol-lowering potential of LDLR gene transfer, we also examined whether mice that received the treatment would develop an antibody response to the newly expressed LDLR as was observed with FG-Ad and AAV. Furthermore, we compared the therapeutic efficacy of LDLR versus VLDLR. 10, 11, 15 Treatment end points included plasma cholesterol concentration as well as the extent of atherosclerotic lesion involvement in the treatment and control groups. Finally, we carried out a long-term follow-up study of mice treated at a relatively young age of 12 weeks to examine the efficacy of HD-Ad-LDLR treatment.
Results

Production and characterization of HD-Ad vectors
Rhesus macaque LDLR and VLDLR cDNAs were cloned by RT-PCR using total cellular RNA prepared from liver and heart, respectively (GenBank Accession No. AY466854 and AY466855). The homology between human and monkey LDLR was 95%, and between monkey and mouse LDLR, 80%, at the amino acid sequence level. The LDLR gene encodes a signal peptide and a mature peptide that encompasses a ligand-binding domain, an epidermal growth factor homology domain, an O-link sugar domain, a transmembrane domain, and a cytoplasmic domain.
2 Individual domains between human and monkey LDLR exhibit amino-acid sequence identities of 85, 95, 97, 85, 90, and 96%, respectively. Compared to the LDLR, VLDLR is much more highly conserved among different mammalian species. The overall sequence identity between human and monkey VLDLR was 99% and that between monkey and mouse was 97%. We produced HD-Ad-LDLR ( Figure 1a ) and HD-Ad-VLDLR using a serotype 5 helper virus. 15 Transgene expression was driven by the rat phosphoenolpyruvate carboxykinase promoter, which directs liver-specific expression of the transgene. Southern blot analysis of HD-Ad-LDLR and HD-Ad-VLDLR detected no DNA rearrangement or helper Ad in the preparation, indicating o0.2% helper virus contamination (Figure 1b and c, and data not shown for HD-Ad-VLDLR).
Effect of HD-Ad-LDLR and HD-Ad-VLDLR administration on plasma cholesterol level in LDLR À/À mice LDLR À/À mice were fed a high cholesterol diet for 20 weeks to induce basal atherosclerosis before treatment. We then treated them with a single intravenous injection of one of two doses of HD-Ad-LDLR (high dose, 1.5 Â 10 13 VP/kg, n ¼ 10, and low dose, 5 Â 10 12 VP/kg, n ¼ 7) or a low dose of HD-Ad-VLDLR (5 Â 10 12 VP/kg, n ¼ 7). PBS was used as a control (n ¼ 10) as the empty HD-Ad was difficult to purify from the helper, and thus its use was often associated with significant toxicity. Prior experiments demonstrated that empty HD-Ad had no effect on either cholesterol or atherosclerosis in mice. 15 Hepatotoxicity of treatment was assessed by plasma AST and ALT activities, which remained within normal limits (AST: 18-46 IU/l in treated group and 18-39 IU/l in control group; ALT: 6-34 IU/l in treated group and 4-25 IU/l in control group) throughout the experiment.
Plasma cholesterol levels in the high-dose group (1.5 Â 10 13 VP/kg) significantly fell from a baseline level of 14.271.7 mmol/l (550764 mg/dl, mean7s.d., n ¼ 10) to 2.670.4 mmol/l (100717 mg/dl, Po0.001) within the first week, while they only showed a downward trend to 7.872.6 mmol/l (not significant, n ¼ 7) in the low-dose group. At 4 weeks, the plasma cholesterol of HD-Ad-LDLR-treated mice reached a nadir (1.370.4 mmol/l in high-dose group, 2.370.7 mmol/l in low-dose group versus control, Po0.001), while cholesterol levels in the control group remained unchanged (Figure 2a) . The plasma cholesterol in the treatment groups remained significantly lower than that of the controls throughout the experiment. At 24 weeks, plasma cholesterol levels were 3.473.6 mmol/l in the high-dose group (n ¼ 9) and 4.372.2 mmol/l in the low-dose group (n ¼ 6), both significantly lower than that of the control group (16.571.6 mmol/l, n ¼ 8, Po0.001).
HD-Ad-VLDLR treatment (5 Â 10 12 VP/kg) produced maximum cholesterol lowering at 4 weeks (5.370.5 mmol/ l, n ¼ 7) after which plasma cholesterol level gradually increased reaching 7.972.0 mmol/l (305778 mg/dl, n ¼ 3), still substantially lower than that of controls (Po0.001), at 24 weeks. Throughout the experimental period, mice treated with HD-Ad-LDLR had a cholesterol level that was consistently lower than that of mice treated with HD-Ad-VLDLR (Figure 2a ).
Anti-LDLR antibodies in high-dose HD-Ad-treated LDLR À/À mice Despite a rapid drop in plasma cholesterol within 1-2 weeks in all HD-Ad-LDLR-treated LDLR À/À mice, two mice in the high-dose group showed an early return of hypercholesterolemia after B8 weeks (Figure 2b Therefore, the development of anti-LDLR antibodies contributed to the short duration of the plasma lipid response that was observed in mice H1 and H2.
Plasma lipoprotein profile in HD-Ad-LDLR-treated mice
We characterized the plasma lipoproteins in treated and control mice by FPLC at 16 weeks after treatment ( Figure  4a ). In PBS-treated LDLR À/À mice, we observed a minor VLDL peak, a prominent intermediate density lipoprotein (IDL)/LDL peak and a moderate high-density lipoprotein (HDL) peak. In HD-Ad-LDLR-treated mice, the VLDL and IDL/LDL peaks were markedly reduced. There was a minor difference in the HDL peak between PBS and low-dose HD-Ad-LDLR group. Although considerable lowering of the HDL peaks was evident in the high-dose LDLR group, the nonHDL/HDL ratio was markedly reduced, suggesting that HD-Ad-LDLR treatment led to a marked reduction in the atherogenic potential of the plasma lipoproteins. HDL lowering had LDLR gene therapy produces protection against atherosclerosis S Nomura et al also been noted after HD-Ad-VLDLR treatment, possibly reflecting an insufficient transfer of the surface components for HDL assembly. 15 The absence of LDLR leads to impairment in LDL clearance from the circulation. 7, 16, 17 To evaluate the functional activity of hepatic LDLR expression in vivo, we measured the rate of disappearance of injected 125 I-LDL (Figure 4b ). At 4 weeks after treatment, 125 I-LDL disappeared from plasma with a half-life of 1775 min (mean7s.d., n ¼ 4) in the high-dose treatment group compared with 5176 min in controls. At 16 weeks after treatment, the rate of disappearance was 1876 min in this group and 4679 min in controls. HD-Ad-LDLR treatment accelerated LDL removal three-fold during both time points.
LDLR expression in the liver 24 weeks after therapy LDLR gene expression was examined in liver samples 24 weeks after treatment. We extracted total cellular RNA from the liver and analyzed LDLR transgene expression by Northern blot (Figure 5a ). LDLR mRNA was readily detected in HD-Ad-LDLR-treated mice (lanes 2 and 3), LDLR gene therapy produces protection against atherosclerosis S Nomura et al but not in control mice (lane 1). Similarly, by Western blot analysis we detected LDLR immunoreactive protein in the liver of HD-Ad-LDLR treated mice, but not in that of control mice (Figure 5b ). In the low-dose group, only the mature form of the LDLR (160 kDa band) was detected, whereas in the high-dose group, both the mature and immature incompletely glycosylated (120 kDa band) forms were present.
2
Hepatic LDLR expression inhibits aortic atherosclerotic lesion progression in LDLR À/À mice
We measured the extent of aortic atherosclerosis in the different treatment groups by computer-assisted morphometry ( Figure 6 ). In all groups, treatment was preceded by 20 weeks of atherogenic diet feeding. One subgroup was killed at this time to determine the degree of background atherosclerosis at the time of therapy.
Aortas were slit open from the arch to the iliac bifurcation and stained with Oil Red O. The aortic atherosclerotic lesion area in the baseline group was 3.571.8 mm 2 (mean7s.d., n ¼ 10). After an additional 24 weeks (44 weeks of atherogenic diet feeding), the affected area increased to 20.9712.1 mm 2 (n ¼ 7) in the PBS group. Aortas of HD-Ad-LDLR groups had far less atherosclerosis than the PBS group, especially in the arch region (data not shown), being 7.173.7 mm 2 in the highdose group (n ¼ 8) and 5.871.0 mm 2 (n ¼ 6) in low-dose group, both significantly smaller than that of the PBS group (Po0.001 and P ¼ 0.001, respectively). A single injection of HD-Ad-LDLR inhibited lesion progression by 80% in the high-dose group. The progression in mean lesion size in the high-dose group after 24 weeks of treatment compared with the pretreatment group (20 weeks of diet) was accounted for entirely by the substantial increased lesion size in H-1 and H-2, the two mice that had developed an elevated anti-LDLR antibody titer and premature recurrence of hypercholesterolemia. If these mice were excluded from the calculation, no progression in mean lesion size was detected between the HD-Ad-LDLR treatment group and the pretreatment group (baseline). The mean aortic lesion size of mice treated with HD-Ad-VLDLR (n ¼ 3) was 7.671.3 mm 2 , also significantly smaller than that of control mice (P ¼ 0.017). In comparison to the 80% inhibition seen in LDLR-treated mice, VLDLR treatment inhibited lesion progression by 54%, a degree of protection that is comparable to that observed in a previous study. 15 Long-term effect of HD-Ad-LDLR treatment in LDLR À/À mice The experiment described above indicates that HD-Ad-LDLR therapy lowered plasma cholesterol and retarded atherosclerosis progression in LDLR À/À mice over a 24-week period. We set out to determine the long-term effectiveness of HD-Ad-LDLR treatment. To maximize the duration of the post-treatment follow-up period, we treated LDLR À/À mice immediately after they had developed a stable hypercholesterolemia, that is, 4 weeks after 8-week-old mice were put on an atherogenic diet. For this long-term experiment we selected a dose of HDAd-LDLR (5 Â 10 12 VP/kg) that was not associated with any measurable antibody formation. We followed the plasma cholesterol of the HD-Ad-LDLR-treated and a group of PBS-treated mice for the lifetime of these animals. The mean plasma cholesterol level in LDLR À/À mice 2 weeks after an i.v. injection of HD-Ad-LDLR fell from 11.772.4 to 2.170.4 mmol/l (n ¼ 11, Po0.001). It decreased further to 1.971.3 mmol/l at 4 weeks, and underwent a slow gradual rise over the next year to B6-7 mmol/l where it remained for the rest of the 2 year experiment (Figure 7a ). We killed six mice from each group after 60 weeks to compare their aortic atherosclerotic lesions, at which time the control mice had developed substantial atherosclerosis (lesion area 15.474.7 mm 2 ) whereas HD-Ad-LDLR-treated mice were virtually lesion-free (0.270.2 mm 2 , P ¼ 0.002) (Figure 7b) . By immunohistochemistry (Figure 7c ), we found that 60-70% hepatocytes in this group expressed immunoreactive LDLR. Although we had started the experiment with 13 control mice and 12 HD-Ad-LDLR treated mice, these mice were found dead periodically with only two control mice surviving after 60 weeks. When one of these control mice was found dead at 92 weeks, we euthanized the remaining control and one HD-Ad-LDLR treated mice for lesion analysis at 93 weeks. The lesion area progressed slightly during 33 weeks on diet in the control mouse, while the aorta of treated mouse was still lesion-free (Figure 7b , lower panel).
With no remaining control mice, we terminated the experiment at 108 weeks (B120 weeks of age) and analyzed the three remaining mice that had been treated with HD-Ad-LDLR. The mean plasma cholesterol level in these mice was 6.371.7 mmol/l (n ¼ 3) (Figure 7a ). By immunohistochemistry, 10-20% hepatocytes contained immunoreactive LDLR (Figure 7c ). The lesions of HDAd-LDLR treated mice at 108 weeks were compared with those of the control mouse euthanized at 93 weeks. By LDLR gene therapy produces protection against atherosclerosis S Nomura et al visual inspection and by Oil Red O staining, the aorta of the control mouse was heavily covered with thick lesions, whereas only scattered lesions were found in treated mice (Figure 7b , lower panel). Quantitative morphometry of cross-sections revealed that atherosclerotic lesion involvement in the valve area was 73% smaller in the treated animals than in the control; it was 85% smaller in the aortic sinus region (Figure 7d ). Corroborating these data based on cross-sectional analysis, en face analysis revealed an 83% inhibition of lesion progression by LDLR gene therapy (Figure 7b ). Due to the fact that the analysis was performed at 108 weeks for the treatment group and at 93 weeks for the control group, the computed degree of protection could be an underestimation.
Histological and immunohistochemical analyses of the atherosclerotic lesions indicated substantial phenotypic differences between the two groups of mice. Control lesions were advanced as well as vulnerable-looking, with more necrotic centers and more extensive vascular cell adhesion molecule-1 (VCAM-1) staining. In contrast, lesions in HD-Ad-LDLR-treated animals displayed features of stable plaques, with a marked reduction in VCAM-1 staining and well-preserved collagen-rich extracellular matrix and increased smooth muscle staining (a-actin) (Figure 8a and b) .
Discussion
The first clinical trial on LDLR gene therapy to treat FH involved an ex vivo approach using retrovirus-mediated gene transfer. The treatment produced marginal effects, though no anti-LDLR antibody was detected. However, LDLR transgene expression was undetectable in liver biopsies. 6 Subsequently, experiments using in vivo LDLR LDLR gene therapy produces protection against atherosclerosis S Nomura et al gene transfer in LDLR À/À mice showed that the FG-Ad and AAV-mediated gene transfer uniformly led to the appearance of anti-LDLR antibodies, 10, 11 which probably contributed to the short-lived nature of the hypocholesterolemic response to LDLR therapy using those vectors. Two different laboratories had used FG-Ad to transfer the VLDLR instead of the LDLR gene to LDLR À/À mice and found good reversal of hypercholesterolemia and an absence of any anti-LDLR antibody formation.
11, 18 Chen et al 10 further found that AAV-VLDLR treatment produced a much better response than did AAV-LDLR in LDLR À/À mice, and attributed the poor response to AAV-LDLR-induced anti-LDLR antibodies in mice treated with the latter vector.
In this communication, we found that HD-Ad-LDLR injection in LDLR À/À mice led to the appearance of anti-LDLR antibodies in a substantial minority (20%) of the high-dose treated mice but none of the low-dose treated mice. The substantially lower dose of HD-Ad-LDLR that failed to induce antibody formation was also highly effective in reversing the hypercholesterolemia ( Figure  2a) . The antibody titer in the high-dose experiments was significantly above background, but was three orders of magnitude lower than that seen following FG-Ad-LDLR treatment, indicating that the marked proinflammatory adenoviral protein expression following FG-Ad-LDLR gene transfer could have acted as an adjuvant that stimulated antibody production in these mice. We note that the use of a CMV promoter in the FG-Ad-LDLR also could have resulted in transgene expression in antigenpresenting cells, contributing to the strong immune response in FG-Ad-LDLR-treated mice. The moderate anti-LDLR antibody titer observed in two of the HD-Ad-LDLR-treated mice was associated with premature return of the hypercholesterolemia in these animals. These observations suggest that antibodies against the transgene product play an important role in curtailing the therapeutic response to FG-Ad-LDLR. The use of a CMV enhancer/chicken b-actin promoter for the AAVmediated LDLR transfer by Chen et al 10 could have contributed to antibody formation. Thus, the anti-LDLR antibodies induced by AAV-LDLR might have contributed to the short-lived response in the report. However, the very poor transduction efficiency of AAV of only 2-5% of the liver cells likely also played a role in the failure of the treatment strategy. 10 The current investigation showed that, in the absence of antibody formation, HDAd-LDLR is more effective than HD-Ad-VLDLR in lowering plasma cholesterol in LDLR À/À mice ( Figure  2a ). This is not unexpected because LDLR binds with high affinity to both apoE and apoB100-containing lipoproteins, whereas VLDLR binds with lower affinity solely to apoE-containing lipoproteins. This difference underlies the fact that VLDLR mediates the uptake of only IDL but not LDL, whereas LDLR mediates the uptake of both IDL and LDL. 19 We used low-dose HD-Ad-LDLR therapy to treat LDLR À/À mice at an early age and followed the animals the duration of their lives. With this strategy, HD-Ad-LDLR therapy might have prolonged the lifespan of these mice, as 2 years after treatment the only surviving mice were those that had received the HD-Ad-LDLR. Furthermore, the treatment inhibited the progression of aortic atherosclerotic lesions by 480%. Therefore, a single injection of HD-Ad-LDLR led to stable long-term protection of LDLR À/À mice against atherosclerosis. Atherosclerosis is a slowly progressive clinical condition punctuated by catastrophic events, such as myocardial infarction. Medium-sized atherosclerotic vessels such as the coronary arteries are susceptible to acute occlusion as a result of plaque rupture and thrombosis, events that are thought to occur much more commonly in vulnerable-looking lesions. [20] [21] [22] [23] We found that, in addition to a marked inhibition of atherosclerotic lesion LDLR gene therapy produces protection against atherosclerosis S Nomura et al progression, atherosclerotic plaques in HD-Ad-LDLRtreated mice displayed a more stable-looking phenotype. Our findings are consistent with the recent studies that have shown that long-term lipid lowering contributes to plaque stabilization, but does not necessarily reduce the lesion size. [24] [25] [26] Lesion remodeling may be an important therapeutic goal if HD-Ad-LDLR therapy ever comes to clinical trial, since the incidence of acute events is correlated with the phenotype of the lesion; HD-Ad-LDLR may prevent acute coronary events more effectively by simultaneously inhibiting lesion progression and remodeling lesion phenotype than by inhibiting lesion progression alone. Given the long-lived nature of HD-Ad transgene expression and the fact that one can reinject HD-Ads produced with helper Ads of different serotypes, 13, 27 HD-Ad-LDLR offers potential benefits to other currently existing vectors for the treatment of homozygous FH.
Materials and methods
Construction and characterization of HD-Ad-LDLR and HD-Ad-VLDLR Rhesus monkey LDLR and VLDLR cDNAs were cloned by RT-PCR using total cellular RNA prepared from the liver and heart, respectively. Primer used were 5 0 -GAAGGATCCAGAGGCTGCGAGCATGGGG CC-3 0 and 5 0 -GAGAAGCTTGGACTCCAGGCAGATGTT CA-3 0 for LDLR, 5 0 -ACCATCCAGGCGGGCACCAT GGGCA-3 0 and 5 0 -TCCTATTGCCATTGTCCCAACCATT GAA-3 0 for VLDLR. The underlined nucleotides are artificial cloning sites. The cDNAs were both subcloned into the phosphoenolpyruvate carboxykinase (PEPCK) promoter expression cassette and then into pD28 plasmid. 15 Rescue and amplification of the HD-Ad-LDLR were performed by the method of Parks et al 28 using 293Cre66 cells (Schiedner et al, manuscript in preparation). Helper virus contamination and vector DNA rearrangement were analyzed by Southern blot analysis, as described. 15 The FG-Ad vector containing LDLR cDNA driven by a CMV promoter (FG-Ad-LDLR) was produced using standard techniques. 18 
Animals
Female LDLR
À/À mice (6-8 weeks of age) on a C57BL/6 background were purchased from Jackson Laboratory and were fed a diet containing 0.2% (w/w) cholesterol and 10% (v/w) coconut oil prior to vector administration. The diet was maintained throughout the experiments. After 20 weeks of the diet, 10 mice were killed to obtain the initial extent of en face aortic lesion size (baseline group). The remaining mice were divided into four groups: high dose of HD-Ad-LDLR (1.5 Â 10 13 VP/ kg); low dose of HD-Ad-LDLR (5 Â 10 12 VP/kg); HD-Ad-VLDLR (5 Â 10 12 VP/kg); and PBS (control). For the longterm study, mice were fed high cholesterol diet for 4 weeks before vector treatment. Mice were anesthetized with isoflurane before collecting blood from the retroorbital plexus in EDTA-containing tubes after a 5-h fast.
Detection of LDLR gene expression
LDLR expression in the liver was characterized by Northern blot and immunoblot analyses. RNA samples were extracted by using TRIzol (Invitrogen). Northern blot analysis was performed on 50 mg of RNA by using 0.8-kb fragment of LDLR cDNA as a probe. Crude membrane proteins were extracted from the liver as previously described. 18 Western blot analysis was performed using 70 mg of protein. Crude membrane proteins were electrophoresed on 7.5% SDS-polyacrylamide gel (Bio-Rad) and transferred onto a nitrocellulose membrane. Rabbit anti-human LDLR C-terminal peptide antibody (1:5000 dilution) was used as the primary antibody followed by peroxidase-conjugated anti-rabbit IgG (Bio-Rad). The C-terminal peptide antibody was generated by immunizing rabbits with keyhole limpet hemocyanin-conjugated synthetic C-terminal peptide, CTYPSRQMVSLEDDVA. LDLR proteins were detected by chemiluminescence using the ECL kit (Amersham Pharmacia Biotech).
Detection of anti-LDLR antibody in plasma
For detection of anti-LDLR antibody in plasma, immunoblot was carried out. Membrane proteins of FG-Ad-LDLR infected CHO-ldlA7 cells lacking LDLR were extracted 2 days after infection. They were separated on a 7.5% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane. Diluted mouse plasma was used as a primary antibody. Plasma anti-LDLR antibody titer was also measured by ELISA with the modifications previously described. 29 Briefly, 50 ml of membrane proteins containing LDLR (final concentration: 1.25 mg/ ml in PBS) was applied on a 96-well plate and left for 2 h at 371C. After washing with 200 ml of PBS containing 0.05% Tween-20 (PBST), the plate was blocked by incubation with 200 ml of PBST containing 2% skim milk at 41C overnight. After washing, the plate was incubated with serially diluted plasma samples for 1 h, washed, and then 50 ml of peroxidase-conjugated goat anti-mouse IgG (1:5000 dilution, Pierce) was added. After 1 h incubation and washing, substrate was added, and the reaction was stopped 3 min later with 100 ml of 1 M H 2 SO 4 . The titer was set as the reciprocal of highest dilution giving an optical density at 450 nm of greater than 0.1.
Quantification of atherosclerotic lesions, histology, and immunohistochemistry
Aortic en face lesions were evaluated by quantitative morphometry as previously described. 15 Histological and immunohistochemical studies were performed on fresh-frozen OCT-embedded proximal aortic sections (5 mm thick). Immunohistochemistry was performed as described 14 using the following primary antibodies: goat anti-human LDLR, c-20 (Santa Cruz Biotechnology, 1:100); rabbit anti-mouse macrophage (Accurate Chemical); rabbit anti-smooth muscle actin (Spring Bioscience, 1:100); and rabbit anti-mouse VCAM-1 (Santa Cruz Biotechnology, 1:100).
Other procedures
Lipid and FPLC (Amersham Pharmacia Biotech) analyses, and rate of 125 I-LDL disappearance in plasma were determined as previously described. 18 Southern blot analysis has been described. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using a kit (Sigma). Statistical analyses were made LDLR gene therapy produces protection against atherosclerosis S Nomura et al with SigmaStat (SPSS) and statistical significance was assigned at Po0.05.
